Skip to main content

September 2016

 

 

academics

 

Clinical research courses

Sun Pharma announced the initiation of a phased transfer of manufacturing & marketing rights in Japan for the 14 long-listed/established prescription brands acquired from Novartis. These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharma’s subsidiary in Japan beginning October 2016.

In line with the vision of Shri Narendra Modi, Hon’ble Prime Minister of India to eradicate Leprosy from India, Shri J P Nadda, Union Minister of Health and Family Welfare reviewed the National Leprosy Eradication Programme and pursuant to that, Ministry of Health and Family Welfare has launched the biggest Leprosy Case Detection Campaign (LCDC) in the country on 5th September 2016 across 149 districts of 19 states/UTs.

Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.

Amgen and Boehringer Ingelheim announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836909 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma. BI 836909 (AMG 420) is currently in Phase 1 studies. BI 836909 (AMG 420) was originally licensed to Boehringer Ingelheim by Micromet before the company was acquired by Amgen in 2012.

EFFECT OF ASCORBIC ACID ON DISSOLUTION STABILITY OF RIFAMPICIN IN MARKET FIXED DOSE COMBINATION PRODUCTS FOR TUBERCULOSIS

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Subashini Rajaram, Abirami Murugan, Nidhina Raj C.M
Swamy Vivekanandha College of Pharmacy, Namakkal, Tamilnadu, India.
Life Pharmacy, Al Barsha, Dubai-UAE
subababu.r@gmail.com

 

ABSTRACT
Degradation of rifampicin (RIF) to insoluble and poorly absorbed 3-Formyl rifamycin SV (3-FRSV) in acidic environment is a major concern which leads to reduction in the bioavailability of RIF and is further influenced by the presence of isoniazid (INH) in the stomach after ingestion. It is recommended that addition of ascorbic acid (ASC) in dissolution medium, in plasma as antioxidant to stabilize RIF from degradation and also daily intake of ASC to control tuberculosis (TB).Though the effect of ASC on fixed dose combination (FDC) products has not been traversed and hence examined in the present study.  The rate of degradation of RIF to 3-FRSV in the presence of ASC in dissolution medium (0.1 N HCl) on market formulations was estimated by Dual Wavelength UV–Vis. spectrophotometry (DW spectrophotometry) and High performance liquid chromatography (HPLC) method. Addition of ASC in FDC formulations lowered significantly formation of 3-FRSV or degradation of RIF as compared to that without ASC in in-vitro. Our study proposed that co-package of ASC with fixed dose combination products (FDC) can protect RIF degradation in the acidic environment and in-vivo investigation needed to predict the bioavailability of RIF in FDC products in the presence and absence of ASC for effective control of TB.

Walk in for JUNIOR RESEARCH FELLOW in ACTREC

The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC, Kharghar, Navi Mumbai is the new state-of-the-art R&D satellite of the Tata Memorial Centre (TMC), which also includes under its umbrella the Tata Memorial Hospital (TMH), the largest cancer hospital in Asia. ACTREC has the mandate to function as a national centre for treatment, research and education in cancer. TMC is an autonomous grant-in-aid institution of the Department of Atomic Energy (DAE), Government of India. It is registered under the Societies Registration Act (1860) and the Bombay Public Trust Act (1950). Its Governing Council is headed by the Chairman, Atomic Energy Commission, Government of India.

Post: JUNIOR RESEARCH FELLOW (One Post)

Recruitment for Pharmacist under National Health mission | 200 Posts

The establishment of the A.H.K.M TRUST done by professionals to promote professionalism in endowment achievement through choice of competent and efficient cadres of personnel from the clerical to various other grade, promotion and placement of human capital at various tiers for the organizations, carrying out research in the area of human resource management. The Trust not only helps to recognize talent to be sourced from the market through the employment process but also helps to recognize members within organizations with the necessary competencies to cope with roles and responsibilities.

A.H.K.M TRUST, Delii  State has been released notification to recruit the available 111 vacancies of 200  Pharmacist  in various government hospitals

Post : Pharmacist

Walk in interview for Pharmacist and ECG Technician in ESIC General Hospital

Applications are invited only from the retired Paramedical employees from Central Govt./ESI Corporation/Quasi Govt./Municipal Body/Defence etc. of the under mentioned specialties on contract basis for a period of 06 (Six) month or till regular incumbent joins. Whichever is earlier, at ESIC General Hospital, Naroda, Ahmedabad as per the following details:-

Post : ECG Technician(01) & Pharmacist(01)

Work in USP for the post of Scientist II - Biologics

The United States Pharmacopeia (USP) is a non–governmental, official public standards–setting authority for prescription and over–the–counter medicines and other healthcare products manufactured or sold in the United States. USP also sets widely recognized standards for food ingredients and dietary supplements. USP sets standards for the quality, purity, strength, and consistency of these products–critical to the public health. USP's standards are recognized and used in more than 130 countries around the globe. These standards have helped to ensure public health throughout the world for close to 200 years.

Post: Scientist II - Biologics